Daiichi Sankyo’s ENLIVEN Phase 3 Study of Pexidartinib Met Primary Endpoint in TGCT
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the pivotal phase 3 placebo-controlled ENLIVEN (NCT02371369) study of pexidartinib met its primary…
Read More...
Read More...